About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Replimune Group Inc (NQ: REPL )

6.730 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 6.730
Bid (Size) 2.710 (1)
Ask (Size) 8.490 (10)
Prev. Close 6.730
Today's Range 6.730 - 6.730
52wk Range 5.860 - 24.81
Shares Outstanding 46,772,263
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Replimune Group: Q3 Earnings Insights
Via Benzinga
Barclays Maintains Overweight Rating for Replimune Group: Here's What You Need To Know
Via Benzinga

Performance

YTD
-22.38%
-22.38%
1 Month
-7.55%
-7.55%
3 Month
-12.82%
-12.82%
6 Month
-41.38%
-41.38%
1 Year
-65.13%
-65.13%

More News

Read More
Crude Oil Moves Lower; AutoZone Profit Tops Views
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
The Latest Analyst Ratings for Replimune Group
Via Benzinga
Analyst Ratings for Replimune Group
Via Benzinga
Replimune Group Inc. (NASDAQ: REPL) Making Surprising Moves in Monday Session
Via Investor Brand Network
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Dow Falls 100 Points; ISM Services PMI Increases In November
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Replimune (REPL) Stock Down 48% Today?
Via InvestorPlace
US Stocks Down; JM Smucker Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
What's Going On With Cancer-Focused Replimune Stock Today?
Via Benzinga
Recap: Replimune Group Q4 Earnings
Via Benzinga
Analyst Ratings for Replimune Group
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
8 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma
From Incyte
Via Business Wire
Stock Market Rally Broadens Out; Apple Unveils Vision Pro, SEC Sues Binance, Coinbase: Weekly Review
Via Investor's Business Daily
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Amedisys Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
ImmunoGen, Day One Surge On Cancer Drug Updates, But Arcus Crashes
Via Investor's Business Daily
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month
Via Benzinga
Analyst Beefs Up Replimune Price Target As Recent Data Validates Treatment Platform
Via Benzinga
PayPal To Rally Around 47%? Here Are 10 Other Price Target Changes For Monday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.